Trwa ładowanie...
Money.pl
Zaloguj
Notowania
SOPHARMA: strona spółki
5.10.2022, 13:01

SPH report for September 2022

“Sopharma” AD (the Company) notifies that for September 2022 the Company recorded a decrease in sales of 36% compared to the same month of the previous year, incl. 54% decrease in domestic sales and 23% decrease in export sales.

Załączniki

Pobierz załącznik 1

Inne komunikaty

DataTytułKursZmiana
2024-04-25
SPH Publication of Annual consolidated audited financial report of "Sopharma" AD for 2023 in ESF format
13,05
0,00
2024-04-22
SPH Sales revenues of Sopharma AD for March 2024
13,70
0,00
2024-04-01
SPH Presentation of the Annual Audited Individual Financial Statements of “Sopharma” AD as at 31 December 2022
13,40
0,00
2024-03-20
SPH Sales revenues for February 2024
14,40
-3,13
2024-03-12
SPH Incoming transfer from capital increase subject to exercise of warrants from issue BG9200001212
14,00
-1,43
2024-03-11
SPH Notification from "Donev Investments Holding" AD under Art. 19 of Regulation (EU) No. 596/2014 of 08 March 2024 on the acquisition of shares from a capital increase
13,80
+1,45
2024-02-29
SPH Consolidated financial report as of 31 December 2023
13,70
-2,19
2024-02-27
SPH Results of conditional capital increase of Sopharma AD by exercising warrants from an issue with ISIN BG9200001212
13,40
+2,99
2024-02-22
SPH Notification from "Donev Investments Holding" AD under Art. 19 of Regulation (EU) No. 596/2014 of 19 February 2024 on the acquisition of shares from a temporary issue/exercise of warrants
13,75
-0,73
2024-02-22
SPH Notification from "Donev Investments Holding" AD under Art. 19 of Regulation (EU) No. 596/2014 of 19 February 2024 on the exercise of warrants in a capital increase under the condition
13,75
-0,73
Wszystke komunikaty